18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy

Eric C. Ford, Joseph Herman, Ellen Yorke, Richard L. Wahl

Research output: Contribution to journalReview articlepeer-review

118 Scopus citations


Advances in technology have allowed extremely precise control of radiation dose delivery and localization within a patient. The ability to confidently delineate target tumor boundaries, however, has lagged behind. 18F-FDG PET/CT, with its ability to distinguish metabolically active disease from normal tissue, may provide a partial solution to this problem. Here we review the current applications of 18F-FDG PET/CT in a variety of disease sites, including non-small cell lung cancer, head and neck cancer, and pancreatic adenocarcinoma. This review focuses on the use of 18F-FDG PET/CT to aid in planning radiotherapy and the associated benefits and challenges. We also briefly consider novel radiopharmaceuticals that are beginning to be used in the context of radiotherapy planning.

Original languageEnglish
Pages (from-to)1655-1665
Number of pages11
JournalJournal of Nuclear Medicine
Issue number10
StatePublished - Oct 1 2009


  • FDG (fluorodeoxyglucose)
  • IGRT
  • IMRT
  • Radiation therapy


Dive into the research topics of '18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy'. Together they form a unique fingerprint.

Cite this